4//SEC Filing
Celator Pharmaceuticals Inc 4
Accession 0001144204-16-077884
CIK 0001327467operating
Filed
Jan 28, 7:00 PM ET
Accepted
Jan 29, 4:05 PM ET
Size
9.8 KB
Accession
0001144204-16-077884
Insider Transaction Report
Form 4
Mayer Lawrence David
President and Head of Research
Transactions
- Award
Stock Option, Right to Buy
2016-01-27+175,000→ 175,000 totalExercise: $1.32Exp: 2026-01-27→ Common Stock (175,000 underlying) - Award
Stock Option, Right to Buy
2016-01-27+35,677→ 35,677 totalExercise: $1.32Exp: 2026-01-27→ Common Stock (35,677 underlying)
Holdings
- 7,468(indirect: By Spouse)
Common Stock
- 71,594
Common Stock
- 3,631(indirect: By Trust)
Common Stock
Footnotes (2)
- [F1]These options vest as follows: (i) 43,750 options vest on January 27, 2017; and (ii) the remaining 131,250 options vest in 11 consecutive quarterly installments of 10,937 shares vest on the 27th day of each April, July, October and January, beginning April 27, 2017 and continuing through October 27, 2019 and one final installment of 10,943 shares on January 27, 2020.
- [F2]These options vest on the date the Issuer announces analysis of overall survival of Study 301, its Phase 3 clinical study.
Documents
Issuer
Celator Pharmaceuticals Inc
CIK 0001327467
Entity typeoperating
Related Parties
1- filerCIK 0001327467
Filing Metadata
- Form type
- 4
- Filed
- Jan 28, 7:00 PM ET
- Accepted
- Jan 29, 4:05 PM ET
- Size
- 9.8 KB